Valuation: Immatics N.V.

Market Cap 103.75Cr 92Cr 86Cr 78Cr 147.9Cr 9.97TCr 149.27Cr 1.04TCr 403.45Cr 5.1TCr 389.52Cr 381.07Cr 16TCr P/E 2026 *
-3.59x
P/E 2027 * -3.61x
Enterprise Value 75Cr 67Cr 62Cr 57Cr 107.1Cr 7.22TCr 108.09Cr 753.96Cr 292.16Cr 3.69TCr 282.07Cr 275.95Cr 12TCr EV / Sales 2026 *
16.1x
EV / Sales 2027 * 17.7x
Free-Float
76.83%
Yield 2026 *
-
Yield 2027 * -
1 day-10.07%
1 week-9.32%
Current month-13.55%
1 month-19.77%
3 months-23.72%
6 months-26.67%
Current year-27.71%
1 week 7.4
Extreme 7.4
9.16
1 month 7.4
Extreme 7.4
9.56
Current year 7.4
Extreme 7.4
11.94
1 year 7.4
Extreme 7.4
12.41
3 years 3.3
Extreme 3.3
13.77
5 years 3.3
Extreme 3.3
14.9
10 years 0
Extreme 0
18.42
Manager TitleAgeSince
Chief Executive Officer 51 01/01/2019
Director of Finance/CFO 57 01/10/2025
Chief Tech/Sci/R&D Officer - 01/01/2025
Director TitleAgeSince
Director/Board Member 51 01/07/2020
Chairman 70 01/10/2012
Director/Board Member 72 01/07/2020
Date Insider Type Main position Quantity % Market Cap. Importance
26/08/26
Perceptive Advisors LLC
BuyCompany 8,63,060 0.6436%
18/03/26 Other

Chief Financial Officer

3,50,000 0.2611%
18/03/26 Other

Head of Human Resources

2,11,000 0.1574%
Change 5-day change 1-year change 3-year change Capi.($)
-10.07%-9.32%-19.26%-26.95% 103.75Cr
+4.16%+3.04%+49.37%+94.17% 7.42TCr
-3.11%-3.53%+20.19%+81.44% 5.74TCr
+0.89%-0.63%+2.17%+36.19% 4.76TCr
+0.36%+0.81%+342.39%+742.40% 4.43TCr
-0.96%-4.50%+24.96%+35.38% 4.25TCr
-0.20%-0.77%+4.13%+105.50% 4.07TCr
-0.54%+2.93%+9.31%+50.41% 3.1TCr
-2.68%+2.92%+29.33%+22.72% 2.85TCr
+0.05%-1.64%-8.14%-11.37% 2.43TCr
Average -1.21%-1.46%+45.45%+112.99% 3.92TCr
Weighted average by Cap. +0.09%-0.86%+56.76%+137.82%

Financials

2026 *2027 *
Net sales 4.65Cr 4.13Cr 3.86Cr 3.52Cr 6.63Cr 447.39Cr 6.7Cr 47Cr 18Cr 228.71Cr 17Cr 17Cr 734.02Cr 3.96Cr 3.52Cr 3.28Cr 2.99Cr 5.64Cr 380.51Cr 5.69Cr 40Cr 15Cr 194.52Cr 15Cr 15Cr 624.29Cr
Net income -29Cr -26Cr -24Cr -22Cr -41Cr -2.76TCr -41Cr -288.42Cr -111.76Cr -1.41TCr -107.9Cr -105.56Cr -4.53TCr -31Cr -28Cr -26Cr -23Cr -44Cr -2.98TCr -45Cr -310.74Cr -120.41Cr -1.52TCr -116.25Cr -113.73Cr -4.88TCr
Net Debt -29Cr -25Cr -24Cr -22Cr -41Cr -2.75TCr -41Cr -287.21Cr -111.29Cr -1.41TCr -107.45Cr -105.12Cr -4.51TCr -34Cr -30Cr -28Cr -26Cr -48Cr -3.26TCr -49Cr -339.91Cr -131.71Cr -1.66TCr -127.17Cr -124.4Cr -5.34TCr
Logo Immatics N.V.
Immatics N.V. is a clinical-stage biopharmaceutical company. The Company is primarily engaged in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics.PRAME is a target expressed approximately 50 cancers. Its PRAME franchise includes approximately three product candidates, two therapeutic modalities and three combination therapies that target PRAME: anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy, IMA203CD8 PRAME cell therapy, IMA402 PRAME bispecific as monotherapy, in combination with immune checkpoint inhibitors, in combination with IMA401 MAGEA4/8 bispecific as well as anzu-cel in combination with Moderna’s PRAME mRNA designed to enhance cell therapy. The Company has approximately two technology platforms for target and T Cell Receptor (TCR) discovery.
Employees
704
Date Price Change Volume
02/26/02 $7.590 -10.07% 12,56,980
01/26/01 $8.440 -3.87% 6,39,726
30/26/30 $8.780 +2.57% 18,98,932
29/26/29 $8.560 +0.71% 6,44,378
28/26/28 $8.500 +1.55% 14,67,544
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
7.590USD
Average target price
17.63USD
Spread / Average Target
+132.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMTX Stock